Q-omics provides the consensus-scored TIMM17B profile across patient tissues and cancer cell-line models. TIMM17B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TIMM17B is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, TIMM17B protein abundance shows 24,503 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, COAD, and LSCC as cancer lineages where TIMM17B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM17B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM17B survival associations across molecular data types. TIMM17B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM17B RNA expression–survival associations across cancer types. High TIMM17B expression shows unfavorable associations in KICH, LIHC, UCS and LUAD, but favorable associations in OV and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for TIMM17B RNA expression.
This table summarizes TIMM17B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 11. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TIMM17B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM17B shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, LUSC, LUAD and HNSC. The COAD box plot shows higher TIMM17B RNA expression in tumor versus normal tissue (log2 FC = +1.290, t-test p < 0.001).
This table shows molecular features associated with TIMM17B in patient tissues and cancer cell lines. In patient samples, TIMM17B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMM17B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
